CyBio and Promega sign Collaboration Agreement for the Development of High-Throughput Applications

21-Jun-2007

CyBio AG and Promega Corporation have signed a long-term collaboration agreement for the joint development and co-marketing of applications on CyBio's liquid handling instruments. CyBio maintains the co-operation with a partner who develops and distributes worldwide highly specific reagents, kits and assays for gene, protein and cell analysis. The co-operation's goal is to jointly develop validated application protocols and to market those for high-throughput screening processes in drug development and life science research.

One topic of the collaboration focuses on the automation of Promega's cell-based multiplex-assays. Such assays deliver increased data quality in toxicity studies of potential drug compounds at lower costs.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic World Cell Analysis

Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.

10+ products
5+ whitepaper
10+ brochures
View topic world
Topic World Cell Analysis

Topic World Cell Analysis

Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.

10+ products
5+ whitepaper
10+ brochures

Last viewed contents

Rheoscience and Dr. Reddy's commence the first Phase III trial of Balaglitazone (DRF 2593) - Balaglitazone is a novel TZD candidate for the treatment of diabetes mellitus

Real-Time Monitoring of Bioprocesses - IRUBIS closes EUR 2.8m seed round led by HTGF, Verve Ventures and Ventura BioMed Investors

Real-Time Monitoring of Bioprocesses - IRUBIS closes EUR 2.8m seed round led by HTGF, Verve Ventures and Ventura BioMed Investors

Acambis extends Sanofi Pasteur licensing agreement on single-dose JE vaccine to India and Indian subcontinent

Exiqon A/S wins prestigious Ernst & Young Entrepreneur of the Year Award

Bio-Rad Announces Receipt of New Ruling in Applied Biosystems Patent Infringement Dispute

Sandoz completes acquisition of EBEWE Pharma, improving global patient access to affordable injectable cancer medicines - Sandoz to focus on quick and seamless integration for customers and employees

Eckert & Ziegler acquires Vitalea Science Inc. as Part of Strategic Move into Innovative Pharmaceutical Services

Albumin preserves kidney function and improves survival in abdominal infection of liver disease

Transition Therapeutics Announces Appointment of Vice-President of Clinical Operations

UCB to sell its U.S. specialty generics business Kremers Urban for US$ 1,525 million

Evotec and Novo Nordisk form research alliance in diabetes and obesity

CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema - Phase I/II study to establish safety and clinical pharmacology with various doses of subcutaneous formulation of human C1-esterase inhibitor